XENE - Xenon Pharmaceuticals Inc.

56.4
-0.690   -1.223%

Share volume: 652,828
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$57.09
-0.69
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 2%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.29%
1 Month
4.91%
3 Months
39.24%
6 Months
32.64%
1 Year
64.52%
2 Year
42.69%
Key data
Stock price
$56.40
P/E Ratio 
0.00
DAY RANGE
$55.66 - $57.00
EPS 
-$4.36
52 WEEK RANGE
$28.19 - $63.95
52 WEEK CHANGE
$55.43
MARKET CAP 
3.463 B
YIELD 
N/A
SHARES OUTSTANDING 
83.190 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$875,640
AVERAGE 30 VOLUME 
$1,062,752
Company detail
CEO: Ian C. Mortimer
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.

Recent news